Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
- autoimmune diseases
This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
MM-C and CB are joint first authors.
Handling editor Josef S Smolen
MM-C and CB contributed equally.
Correction notice This article has been corrected since it published Online First. The author affiliations have been corrected.
Contributors All authors contributed to manuscript preparation and approved the submitted version.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests MMC reports grant and personal fees from Actelion, Biogen, Bayer, Boehringer Ingelheim, CSL Behring, Eli-Lilly, outside the submitted work. CB reports consultancy fee from Actelion, Eli Lilly. YA reports personal fees from Actelion, Bayer, BMS, Boehringer and Curzion, and grants and personal fees from Inventiva, Roche and Sanofi. MC; NSD: none. LD received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI. CPD has received consultancy fees and/or research grant funding from Actelion, GlaxoSmithKline, Bayer, Sanofi-Aventis, Inventiva, Boehringer Ingelheim, Roche, CSL Behring, UCB Pharma, Leadiant Biosciences, Corbus, Acceleron. OD had consultancy relationship and/or has received research funding from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd, CSL Behring, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Target Bio Science and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). Grants (2 Jahre) from Actelion, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma Patent issued: mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143). Comment: To investigate potential treatments of scleroderma and its complications. DF has received consulting fees, speaking fees and/or honoraria from Pfizer and research support from Regeneron, Gilead and Seattle Genetics. DEF: Grant/Research Support Corbus, Galapagos GSK, Pfizer, Talaris, CSL Behring, Mitsubishi; Consultant Actelion, Amgen, Corbus, Galapagos, Novartis, Pfizer, Roche/Genentech, Talaris, CSL Behring, Boehringer Ingelheim; DK reports personal fees from Actelion, Abbvie, Bayer, Boehringer-Ingelheim, Chemomab, Corbus, CSL Behring, Genentech/Roche, Gilead, GSK, Mitsubishi Tanabi, Sanofi-Aventis, UCB Pharma. He reports grants from Bayer, Boehringer-Ingelheim, Genentech/Roche, Pfizer, Sanofi-Aventis and has stock options in Eicos Sciences. MK has received consultancy fees and/or research grant funding from Abbvie, Actelion Pharmaceuticals, Astellas, Bayer, Boehringer Ingelheim, Chugai, Corbus, CSL Behring, Eisai, Mochida, Nippon Shinyaku, Novartis, Ono, Pfizer, Reata and Tanabe-Mitsubishi. SP reports SAB from Abpro. TK recieved consultancy fee and grant funding from Actelion.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.